Farletuzumab
Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ[2] which is being investigated for the treatment of ovarian cancer.[3][4]
This drug was developed by Morphotek, Inc.
It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.[2]
Mechanism of action
Farletuzumab uses the following mechanisms of action:[2]
- Antibody-dependent cellular cytotoxicity
- Complement-dependent cytotoxicity
- Inhibition of interaction between FRα and Lyn kinase
- Induces cell death associated with autophagy
Adverse effects
Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.[2]
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association.
- ^ a b c d Sato S, Itamochi H (2016-03-07). "Profile of farletuzumab and its potential in the treatment of solid tumors". OncoTargets and Therapy. 9: 1181–8. doi:10.2147/OTT.S98242. PMC 4789847. PMID 27022278.
- ^ Clinical trial number NCT00738699 for "Phase II Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer" at ClinicalTrials.gov
- ^ Clinical trial number NCT00849667 for "Phase III Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse" at ClinicalTrials.gov
- v
- t
- e
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e